In this section
Clinical trials
- Participate in a clinical trial
- For medical professionals
- Active clinical trials for pediatric cancers
- Alpha Beta T-cell and B-cell depleted allogeneic transplantation followed by Blinatumomab therapy for high-risk B-Acute Lymphoblastic Leukemia pilot study
- Blinatumomab bridging therapy in high-risk B-ALL clinical trial
- CAR-20/19-T cells in pediatric and young adult patients with relapsed/refractory B Cell Acute Lymphoblastic Leukemia (CAR-20/19-T) phase 1 clinical trial
- Unrelated and partially matched related donor peripheral stem cell transplantation for patients with hematologic malignancies clinical trial
- Early stage research
Active clinical trials
Clinical Trials - Diseases by specialty group
Early Phase Trials (Phase I and II) 43
-
Protocol ID
- Associated disease
- Title
-
BCC-015
- Early Phase Trials (Phase I and II)
- Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
-
BMTCTN-1904
- Early Phase Trials (Phase I and II)
- BMTCTN-1904 Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for the Treatment of Bone Marrow Failure Diseases
-
CHOP-ALPHABETA
- Early Phase Trials (Phase I and II)
- Unrelated and Partially Matched Related Donor Peripheral Stem Cell Transplantation with a/b T Cell and B Cell Depletion for Patients with Hematologic Malignancies
-
COG-AALL1521
- Early Phase Trials (Phase I and II)
- A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
-
COG-AALL1721
- Early Phase Trials (Phase I and II)
- A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy
-
COG-AALL1821
- Early Phase Trials (Phase I and II)
- AALL1821 - A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC# 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >= 1 to < 31 Years Old with First Relapse
-
COG-ACNS1422
- Early Phase Trials (Phase I and II)
- A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-RiskWNT-Driven Medulloblastoma Patients
-
COG-ADVL1312
- Early Phase Trials (Phase I and II)
- A Phase 1/2 Study of AZD1775 (MK-1775, IND# 121422) in Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors
-
COG-ADVL1412
- Early Phase Trials (Phase I and II)
- A Phase 1/2 Study of Nivolumab (Ind# 124729) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
-
COG-ADVL1414
- Early Phase Trials (Phase I and II)
- A Phase 1 Study of Selinexor (KPT-330, IND #125052), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
-
COG-AHOD1721
- Early Phase Trials (Phase I and II)
- Risk-based, Response-adapted, Phase II Open-label Trial of Nivolumab + Brentuximab Vedotin (N + Bv) for Children, Adolescents, and Young Adults with Relapsed/refractory (R/R) CD30 + Classic Hodgkin Lymphoma (cHL) After Failure of First-line Therapy, Followed by Brentuximab + Bendamustine (Bv + B) for Participants with a Suboptimal Response. CheckMate 744: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation
-
COG-ANBL1821
- Early Phase Trials (Phase I and II)
- A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma
-
COG-ANHL12P1
- Early Phase Trials (Phase I and II)
- A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND # 117117
-
COG-ANHL1522
- Early Phase Trials (Phase I and II)
- A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-specific
Cytotoxic T-Lymphocytes (LMP-TC, IND # 17068) in Pediatric Solid Organ Recipients (SOT)
with EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD)
-
COG-AOST1321
- Early Phase Trials (Phase I and II)
- Phase 2 Study of Denosumab (IND#127430, NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma
-
COG-AOST1421
- Early Phase Trials (Phase I and II)
- A Phase II Study of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038, IND# 4308) in Combination with Sargramostim (GM-CSF) in Patients with Recurrent Osteosarcoma
-
COG-APEC1621A
- Early Phase Trials (Phase I and II)
- NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions
-
COG-APEC1621B
- Early Phase Trials (Phase I and II)
- NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Tumors Harboring FGFR1/2/3/4 Alterations
-
COG-APEC1621D
- Early Phase Trials (Phase I and II)
- NCI-COG PEDIATRIC MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors
-
COG-APEC1621E
- Early Phase Trials (Phase I and II)
- NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Selumetinib (Azd6244 Hydrogen Sulfate) in Patients with Tumors Harboring Activating MAPK Pathway Mutations
-
COG-APEC1621F
- Early Phase Trials (Phase I and II)
- NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations
-
COG-APEC1621H
- Early Phase Trials (Phase I and II)
- NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes
-
COG-APEC1621I
- Early Phase Trials (Phase I and II)
- NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes
-
COG-APEC1621K
- Early Phase Trials (Phase I and II)
- NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients with Tumors Harboring IDH1 Mutations
-
COG-APEC1621SC
- Early Phase Trials (Phase I and II)
- NCI - COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
-
COG-AREN1721
- Early Phase Trials (Phase I and II)
- A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
-
COG-AREN1921
- Early Phase Trials (Phase I and II)
- Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
-
COG-ARST1921
- Early Phase Trials (Phase I and II)
- A Safety, Pharmacokinetic and Efficacy Study of a Gamma-Secretase Inhibitor, Nirogacestat (PF-03084014; IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors
-
DFCI-KPT-330
- Early Phase Trials (Phase I and II)
- Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML
-
IIT-BURKE-BBT
- Early Phase Trials (Phase I and II)
- Blinatumomab Bridging Therapy in High-Risk B-Acute Lymphoblastic Leukemia
-
IIT-MCGONIGLE-ONA-NEUROPATHY
- Early Phase Trials (Phase I and II)
- Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy
-
IIT-PHELAN-BBT-HCT
- Early Phase Trials (Phase I and II)
- Alpha/Beta T-cell and B-cell Depleted Allogeneic Transplantation Followed by Blinatumomab Therapy for High-Risk B-Acute Lymphoblastic Leukemia
-
IIT-TALANO-CART-ALL
- Early Phase Trials (Phase I and II)
- Phase 1 Study of Redirected Autologous T Cells Engineered to Contain an Anti-CD19 and Anti-CD20 scFv Coupled to CD3-zeta; and 4-1BB Signaling Domains in Pediatric and Young Adult Patients with Relapsed and/or Refractory CD19 or CD20 B-cell Acute Lymphoblastic Leukemia
-
NYMC-571
- Early Phase Trials (Phase I and II)
- The Safety and Efficacy of Prophylactic Defibrotide Administration in Children, Adolescents, and Young Adults with Sickle Cell Disease or Beta Thalassemia Following Myeloablative Conditioning (MAC) and Haploidentical Stem Cell Transplantation Utilizing CD34 Enrichment and T-Cell (CD3) Addback (IND 127812)
-
PBMTC-ONC1401
- Early Phase Trials (Phase I and II)
- The Role of KIR-favorably Mismatched Haploidentical Transplantation and KIR-polymorphisms in Determining Outcomes of Children with ALL/AML/MDS Undergoing Allogeneic Hematopoietic Cell Transplantation
-
PIDTC-CSIDE
- Early Phase Trials (Phase I and II)
- A randomized trial of low versus moderate exposure busulfan for infants with severe combined immunodeficiency (SCID) receiving TCR alpha beta+/CD19+ depleted transplantation: A Phase II study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC) PIDTC CSIDE Protocol (Conditioning SCID Infants Diagnosed Early) PBMTC NMD 1801
-
PTCTC-ONC1701-ENDRAD
- Early Phase Trials (Phase I and II)
- A Phase II Pilot Trial to Estimate Survival after a Non-total Body Irradiation (TBI) Based Conditioning Regimen in Patients Diagnosed with B-acute Lymphoblastic Leukemia (ALL) Who are Pre-allogeneic Hematopoietic Cell Transplantation (HCT) Next-generation-sequence (NGS) Minimal Residual Disease (MRD) Negative
-
SPOC-2012-001
- Early Phase Trials (Phase I and II)
- Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
-
SPRINGWORKS-MEK-NF-201
- Early Phase Trials (Phase I and II)
- A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Patients with Neurofibromatosis Type 1 (NF1) associated Inoperable Plexiform Neurofibromas (PNs) that are Progressing and/or Causing Significant Morbidity
-
TACL-2016-003-EPIGENETIC
- Early Phase Trials (Phase I and II)
- Epigenetic Reprogramming in Relapse AML: A Phase 1 Study of Decitabine and Vorinostat Followed by Fludarabine, Cytarabine and G-CSF (FLAG) in Children and Young Adults with Relapsed/Refractory AML
-
TACL-MARQIBO
- Early Phase Trials (Phase I and II)
- A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination with UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults with Relapse of Acute Lymphoblastic Leukemia
-
TACL-ONYX-CFZ008
- Early Phase Trials (Phase I and II)
- Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia
-
TACL-T2016-002
- Early Phase Trials (Phase I and II)
- A Phase I/II Study of Nivolumab in Combination with 5-azacytidine in Pediatric Patients with Relapsed/refractory Acute Myeloid Leukemia (BMS Reference CA209-9JY) IND #140029
Contact us
For more information about cancer and blood disorders clinical trials, email us or call
(414) 955-4727
Get a second opinion
It's important to know what your options are. We can provide expert opinions to verify or give more information about an initial diagnosis. Contact us today.
Why participate in clinical trials?